# Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL

> **NCT00655837** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 33 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** SGN-40
- **DRUG:** rituximab
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00655837
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00655837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00655837, "Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00655837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*